Works matching IS 23988835 AND DT 2019 AND VI 2 AND IP 3
Results: 6
Ombitasvir/paritaprevir/ritonavir plus ribavirin for 24 weeks in patients with HCV GT4 and compensated cirrhosis (AGATE‐I Part II).
- Published in:
- Health Science Reports, 2019, v. 2, n. 3, p. N.PAG, doi. 10.1002/hsr2.92
- By:
- Publication type:
- Article
Issue Information.
- Published in:
- Health Science Reports, 2019, v. 2, n. 3, p. N.PAG, doi. 10.1002/hsr2.64
- Publication type:
- Article
Transparency and reproducibility: A step forward.
- Published in:
- Health Science Reports, 2019, v. 2, n. 3, p. N.PAG, doi. 10.1002/hsr2.117
- By:
- Publication type:
- Article
Invisible partners in care: Snapshot of well‐being among caregivers receiving comprehensive support from Veterans Affairs.
- Published in:
- Health Science Reports, 2019, v. 2, n. 3, p. N.PAG, doi. 10.1002/hsr2.112
- By:
- Publication type:
- Article
Direct‐acting antiviral therapy for chronic hepatitis C virus genotype 4 infection: Exploring new regimens.
- Published in:
- Health Science Reports, 2019, v. 2, n. 3, p. N.PAG, doi. 10.1002/hsr2.106
- By:
- Publication type:
- Article
Bevacizumab as a steroid‐sparing agent during immunotherapy for melanoma brain metastases: A case series.
- Published in:
- Health Science Reports, 2019, v. 2, n. 3, p. N.PAG, doi. 10.1002/hsr2.115
- By:
- Publication type:
- Article